Interferon-α-Induced TRAIL on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection

Gastroenterology

Volumn 138, Issue 5, 2010, Pages

  Stegmann, Kerstin A ^a,b   Björkström, Niklas K ^b   Veber, Heike ^a   Ciesek, Sandra ^a,c   Riese, Peggy ^d   Wiegand, Johannes ^a   Hadem, Johannes ^a   Suneetha, Pothakamuri V ^a   Jaroszewicz, Jerzy ^a   Wang, Chun ^a   Schlaphoff, Verena ^a   Fytili, Paraskevi ^a   Cornberg, Markus ^a   Manns, Michael P ^a   Geffers, Robert ^d   Pietschmann, Thomas ^c   Guzmán, Carlos A ^d   Ljunggren, Hans Gustaf ^b   Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

Hepatitis C; Interferon Alfa; NK Cells; TRAIL

Indexed keywords

ALPHA INTERFERON; CD56 ANTIGEN; PEGINTERFERON; RECOMBINANT ALPHA2B INTERFERON; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VIRUS RNA;

ADULT; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPATITIS C; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION CONTROL; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

EID: 77951861128     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.01.051     Document Type: Article

References (32)

1. Shepard C.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5 (2005) 558-567
2. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 36 (2002) S21-S29
3. Wiegand J., Deterding K., Cornberg M., et al. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. J Antimicrob Chemother 62 (2008) 860-865
4. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 119 (2009) 1745-1754
5. Wedemeyer H., He X.S., Nascimbeni M., et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 169 (2002) 3447-3458
6. Crotta S., Stilla A., Wack A., et al. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 195 (2002) 35-41
7. Manns M.P., Wedemeyer H., and Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55 (2006) 1350-1359
8. Herrmann E., Lee J.H., Marinos G., et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37 (2003) 1351-1358
9. Ljunggren H.G., and Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 11 (1990) 237-244
10. Lanier L.L. The origin and functions of natural killer cells. Clin Immunol 95 (2000) S14-S18
11. Norris S., Collins C., Doherty D.G., et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol 28 (1998) 84-90
12. Smyth M.J., Cretney E., Kelly J.M., et al. Activation of NK cell cytotoxicity. Mol Immunol 42 (2005) 501-510
13. Golden-Mason L., and Rosen H.R. Natural killer cells: primary target for hepatitis C virus immune evasion strategies?. Liver Transpl 12 (2006) 363-372
14. Nattermann J., Feldmann G., Ahlenstiel G., et al. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 55 (2006) 869-877
15. Yoon J.C., Shiina M., Ahlenstiel G., et al. Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology 49 (2009) 12-21
16. Sato K., Hida S., Takayanagi H., et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 31 (2001) 3138-3146
17. Wiegand J., Buggisch P., Boecher W., et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 43 (2006) 250-256
18. Pfoertner S., Jeron A., Probst-Kepper M., et al. Signatures of human regulatory T cells: an encounter with old friends and new players. Genome Biol 7 (2006) R54
19. Steinmann E., Brohm C., Kallis S., et al. Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. J Virol 82 (2008) 7034-7046
20. Pietschmann T., Kaul A., Koutsoudakis G., et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 103 (2006) 7408-7413
21. Cooper M.A., Fehniger T.A., and Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol 22 (2001) 633-640
22. Hietakangas V., Poukkula M., Heiskanen K.M., et al. Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP. Mol Cell Biol 23 (2003) 1278-1291
23. Takeda K., Hayakawa Y., Smyth M.J., et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7 (2001) 94-100
24. Kayagaki N., Yamaguchi N., Nakayama M., et al. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 189 (1999) 1451-1460
25. Ciesek S., Liermann H., Hadem J., et al. Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. J Viral Hepat 15 (2008) 200-211
26. Dunn C., Brunetto M., Reynolds G., et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 204 (2007) 667-680
27. Sarasin-Filipowicz M., Oakeley E.J., Duong F.H., et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105 (2008) 7034-7039
28. Ahlenstiel G., Titerence R.H., Koh C., et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 138 (2010) 325-335
29. Pilli M., Zerbini A., Penna A., et al. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology 133 (2007) 1132-1143
30. Walczak H., Miller R.E., Ariail K., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5 (1999) 157-163
31. Ganten T.M., Koschny R., Sykora J., et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12 (2006) 2640-2646
32. Volkmann X., Fischer U., Bahr M.J., et al. Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 46 (2007) 1498-1508